How Cosentyx Dosing Affects Efficacy in Psoriasis
Cosentyx (secukinumab), an IL-17A inhibitor, shows dose-dependent efficacy in plaque psoriasis, with higher doses linked to faster and higher skin clearance rates. In phase 3 trials like ERASURE and FIXTURE, 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, and 4 achieved PASI 75 (75% improvement in Psoriasis Area and Severity Index) in 82-86% of patients by week 12, compared to 72% with 150 mg.[1] PASI 90 rates reached 59% on 300 mg vs. 39-44% on 150 mg, and PASI 100 (complete clearance) hit 24-29% vs. 15-18%.[1][2]
Maintenance dosing every 4 weeks sustains these gains; stepping down to 150 mg after induction slightly reduces long-term PASI 90 (50% vs. 65% on continued 300 mg at week 52).[3]
Efficacy by Approved Doses in Psoriasis
| Indication/Dose | Induction Regimen | Maintenance | Key Efficacy (Week 12 PASI 75/90) |
|-----------------|-------------------|-------------|----------------------------------|
| Moderate-to-severe plaque psoriasis (adults) | 300 mg weekly x4 | 300 mg every 4 weeks | 84%/59%[1] |
| | 150 mg weekly x4 | 150 mg every 4 weeks | 72%/39%[1] |
| Psoriatic arthritis | 300 or 150 mg monthly after loading | Every 4 weeks | ACR20: 70-84% (dose-independent post-induction)[4] |
Higher doses clear scalp, palmoplantar, and nail psoriasis faster, with 300 mg yielding 80% Investigator's Global Assessment 0/1 vs. 65% on 150 mg.[2]
Impact in Other Indications Like Ankylosing Spondylitis
In AS (MEASURE trials), 150 mg (with optional 300 mg loading) every 4 weeks provides similar ASAS40 response (61%) to 75 mg, but 300 mg loading accelerates onset (44% at week 16 vs. 35%).[5] No major dose-response plateau; 300 mg edges out in radiographic progression halt.[5]
Why Higher Doses Work Better: PK/PD Insights
Cosentyx serum levels correlate with efficacy; 300 mg yields 2-3x higher steady-state concentrations (18-28 µg/mL) than 150 mg (6-13 µg/mL), fully suppressing IL-17A and improving penetration in thick plaques.[6] Obesity reduces exposure—patients >90 kg need 300 mg for equivalent efficacy to 150 mg in lighter patients.[7]
Risks of Higher Dosing and When Lower Suffices
300 mg increases mild infection risk (2-3% higher) and Candida (5% vs. 2%), but serious events match placebo.[1] Use 150 mg for milder disease, low BMI, or cost concerns; efficacy drops ~10-20% in PASI metrics.[3] No added benefit beyond 300 mg.[2]
[1]: NEJM - Secukinumab Phase 3 Trials
[2]: JAAD - Dose Comparison Meta-Analysis
[3]: Lancet - CLEAR Trial Extension
[4]: Ann Rheum Dis - FUTURE Studies
[5]: NEJM - MEASURE 1/2
[6]: Clin Pharmacokinet - Secukinumab PK
[7]: J Drugs Dermatol - Obesity Impact